Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

NCT00500786 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

BIOLOGICAL: CYT006-AngQb

Sponsor

Cytos Biotechnology AG